**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a study, seven patients (4 men and 3 women) aged 45−69 years were described, who developed COVID-2019 infection during immunosuppressive treatment with azathioprine, mycophenolate mofetil, prednisolone or tacrolimus. One of the seven patients died due to COVID-2019 infection \[*not all dosages stated; routes, duration of treatments to reaction onsets and outcomes not stated*\].

Patient 1: A 48-year-old man had undergone deceased donor kidney transplantation in 1989. He had been receiving immunosuppressive therapy with azathioprine 75mg once daily and prednisolone 5mg once daily. During the first week of March 2020, he developed fever, cough and mild shortness of breath. His nose and throat swabs taken on 02 March 2020 tested positive for COVID-2019 infection, which was attributed to the immunosuppressive therapy. He was clinically well and therefore asked to self isolate at home. His immunosuppressive therapy was continued. Subsequently, he recovered completely with a stable kidney function.

Patient 2: A 67-year-old woman, who had insulin dependent type 2 diabetes and end stage renal disease requiring haemodialysis, had undergone deceased donor kidney transplantation in March 2019. Her immunosuppressive therapy included tacrolimus (levels between 5−8 ng/mL, prednisolone 5mg once daily and mycophenolate mofetil 250mg twice daily with several other co-medications. On 05 March 2020, she presented with fever, cough and shortness of breath. A chest X-ray showed bilateral patchy consolidation. Her nose and throat swabs in PCR tested positive for COVID-2019 infection, which was attributed to the immunosuppressive therapy. She was hypoxic with a RR 26 breaths/minute and peripheral oxygen saturation of 86%. Therefore, she was admitted to the intensive therapy unit (ITU). She was commenced on continuous positive airway pressure for type 1 respiratory failure. As her conditioned worsened, she was ventilated. During the admission, her serum CRP was 83 mg/L, Hb was 110 g/L with mild lymphopenia. She was treated with unspecified broad spectrum antibiotics. Mycophenolate mofetil was stopped, and low-dose tacrolimus was continued that was withdrawn 1 day prior to her death. After 3 days of the admission, her serum creatinine level was 225 µmol/L. The findings suggested acute kidney injury. She was stable on the ventilator and showed improvement in lung infiltrates on X-ray. However, on 16 March 2020, she had elevated levels of LDH, serum lactate and CRP. She developed severe metabolic acidosis, which was resistant to venovenous haemodiafiltration probably because of an unspecified intra-abdominal event. On 17 March 2020, her condition worsened rapidly, and she died due to COVID-2019 infection.

Patient 3: A 54-year-old woman had a history of adult polycystic kidney disease and end stage kidney disease. After being on haemodialysis for 7 years, she underwent a deceased donor kidney transplantation in December 2019. Subsequently, she developed cytomegalovirus infection and post-transplant diabetes mellitus. Her immunosuppressive therapy included tacrolimus 11mg twice daily, mycophenolate mofetil 500mg twice daily and prednisolone 5mg once daily. She was receiving several other co-medications. After 3 months of the transplantation, on 10 March 2020, she presented to an emergency department with shortness of breath. Her HR was 105 beats/minute, oxygen saturation was 60% and BP was 190/99mm Hg. Her oxygen saturation improved to 87% after continuous positive airway pressure. Auscultation of the chest demonstrated widespread crepitations, and her chest X-ray revealed bilateral pulmonary infiltrates. She tested positive for COVID-2019 infection, which was attributed to the immunosuppressive therapy. Subsequently, she developed acute kidney injury and acute respiratory distress syndrome. Her condition worsened requiring 8h of intubation and continuous ventilator support. On 10 March 2020, her mycophenolate mofetil therapy was stopped, and on 16 March 2020 tacrolimus was stopped. She was treated with unspecified broad spectrum antibiotics, unspecified antiviral and oseltamivir. She also received cotrimoxazole for pneumocystis. Her serum CRP level improved. Subsequently, she became anuric and continuously required venovenous haemofiltration. Her recent chest X-ray revealed some resolution of the pulmonary infiltrates.

Patient 4: A 65-year-old man, who was wheelchair bound, had hypertensive nephrosclerosis, end stage kidney disease and recurrent thromboembolic events. In August 2018, he underwent a deceased donor kidney transplantation. He had been receiving immunosuppressive therapy with tacrolimus, mycophenolate mofetil and prednisolone. After 17 months of the transplantation, he presented with chest pain and shortness of breath. He was admitted to the ITU, and diagnosed with COVID-19 infection on 15 March 2020. The infection was attributed to the immunosuppressive therapy. His mycophenolate mofetil therapy was withdrawn while prednisolone and tacrolimus were continued. Subsequently, he was transferred to a medical ward, and saturation was maintained with 4−6L oxygen. Thereafter, his kidney function remained stable.

Patient 5: A 69-year-old woman had a history of hypertension, diabetes and end stage kidney disease. She also had a history of peritoneal dialysis and haemodialysis. She underwent a deceased donor kidney transplantation on 29 February 2020. Her immunosuppressive therapy included mycophenolate mofetil, tacrolimus and prednisolone. She was receiving several other co-medications. She presented with diarrhoea, vomiting, shortness of breath and fever on 13 March 2020. On the same day, her chest X-ray revealed shadow to left base which deteriorated on 19 March 2020. On 14 March 2020, she tested positive for COVID-19 infection, which was attributed to the immunosuppressive therapy. She was unwell with BP 166/52mm Hg and oxygen saturation 82% that improved to 97% after 4L oxygen via nasal cannula. She had Hb level 74 g/L, serum fibrinogen level 4.2 g/L and serum N-terminal pro-hormone of brain natriuretic peptide level 5186 ng/L. After 3 days of the admission, her lymphocyte count declined and remained low. Her mycophenolate mofetil therapy was withdrawn on 14 March 2020, and tacrolimus was continued. She was treated with piperacillin/tazobactam, doxycycline, furosemide, paracetamol and blood transfusion. On 15 March 2020, she was admitted to the ITU for respiratory support and required oxygen less than 5 L/minute. On 17 March 2020, she was transferred back to the ward. On 20 March 2020, her serum creatinine level was 138 µmol/L. She remained stable and was managed as inpatient in a general ward.

Patient 6: A 54-year-old man, who had urate nephropathy and hereditary haemolytic anaemia, had undergone kidney transplantation. He had been receiving immunosuppressive therapy with mycophenolate mofetil 500mg twice daily, tacrolimus \[Advagraf\] 3.5mg once daily along with several other co-medications. On 10 March 2020, he presented with fever and cough. On 13 March 2020, he tested positive for COVID-19 infection, which was attributed to the immunosuppressive therapy. His vitals were stable and he was well hydrated. He was treated with paracetamol, and was continued on his regular medications including immunosuppressive therapy. Subsequently, his creatinine elevated from 145 µmol/L to 187 µmol/L, and he developed acute kidney injury. His Hb level was 141 g/L. On 21 March 2020, he was symptomatic with a mild fever and cough. As the symptoms were not improving, the therapy with mycophenolate mofetil was stopped, and he was advised to stay at home.

Patient 7: A 45-year-old man failed second kidney transplantation since September 2017. He had arterial hypertension, and was maintained on immunosuppressive therapy with azathioprine, tacrolimus and prednisolone 10mg once daily as he was a sensitised recipient with 90% panel reactive antibodies. He had previously received mycophenolate mofetil, which was stopped in late 2018 due to GI side effects. Subsequently, he presented with flu-like symptoms, fever and cough since 7 days and shortness of breath since 1 day. On 17 March 2020, he was admitted. During the admission, he was hypoxic with oxygen saturation of 90% on room air and was tachypnoeic. His oxygen saturation was corrected to \>95% after administration of 4 L/minute oxygen via nasal cannula. His throat and nasal swabs tested positive for COVID-19 infection, which was attributed to the immunosuppressive therapy. Subsequently, he developed acute kidney injury, and was lymphopenic. During the admission, his liver function tests were normal, but on day 4 his ALT elevated to 138 U/L. A chest X-ray showed bilateral infiltrates. The therapy with azathioprine was stopped after admission while the dose of tacrolimus was reduced. The dose of prednisolone was increased to 15mg once daily. He required a haemodialysis session. An improvement in his respiratory function was noted. On 23 March 2020, his oxygen saturation was \>95% on 2 L/minute oxygen. Subsequently, he remained haemodynamically stable.
